Spotlight/ Insights CBeyond P2a Data: Nimacimab as Mono and Combination Therapy Date published: October 6, 2025 10:50 am PDT Share Copied! CBeyond Phase 2a topline data highlights nimacimab as monotherapy and in combination with a GLP-1 therapeutic, semaglutide, with weight loss, tolerability and safety outcomes Related Documents: P2a Topline Data Conference Call: Slides P2a Topline Data Conference Call: Transcript